

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/918,715
Filing Date	August 1, 2001
First Named Inventor	Brad St. Croix
Group Art Unit	1614-1642
Examiner Name	FDA C. Yaen
Attorney Docket Number	001107.00134

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CY		V. DE WAARD et al., "Serial analysis of gene expression to assess the endothelial cell response to an atherogenic stimulus", Gene, Vol. 226, No. 1, 1-8-1999, pp. 1-8	
CY		V.E. VELCULESCU et al., "Serial analysis of gene expression", Science, Vol. 270, no. 5235, 10-20-1995, pp. 484-487	
CY		A. LAL et al, "A public database for gene expression in human cancers", Cancer Research, Vol. 59, no. 21 page 5403-7, 1999	
CY		B. ST. CROIX, "Genes expressed in human tumor endothelium", Science, Vol. 289, No. 5482, 8-18-2000, pp. 1197-1292	

Examiner Signature	Christopher H. Y.	Date Considered	4.23.03
--------------------	-------------------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.